Biokinetic model for the calculation of dose coefficients for oral and intravenous administration of 14C labeled drugs

被引:0
|
作者
Krins, A. [1 ]
Fidorra, J. [2 ]
Pleiss, U. [3 ]
Sahre, P. [1 ]
Schoenmuth, T. [1 ]
机构
[1] VKTA Verein Kernverfahrenstech & Analyt Rossendor, Nucl Engn & Analyt Rossendorf Inc, Postfach 51 01 19, D-01314 Dresden, Germany
[2] Bayer AG, Radiat Protect, D-51368 Leverkusen, Germany
[3] Bayer AG, Pharma Prod Dev, D-42096 Wuppertal, Germany
关键词
D O I
暂无
中图分类号
TL [原子能技术]; O571 [原子核物理学];
学科分类号
0827 ; 082701 ;
摘要
A first order biokinetic model is presented for the calculation of dose coefficients from human activity excretion data after intravenous and oral administration of C-14 labeled drugs It is intended for the dose estimation in human studies in drug research, where the number of measurements is low and their uncertainty rather high. The model depends on only 6 parameters that are to be adjusted with the help of the measurement data. A comparison of measured and calculated activities in excreta of four human studies on C-14 labeled drugs revealed considerable agreement, although some limitations have to be accepted. In contrast to the biokinetic model for C-14 in organic compounds recommended by the International Commission on Radiological Protection (ICRP) the present model does not assume a fixed biological half-life of 40 days, but follows the experimental data. In consequence, the resulting dose coefficients differ from the ICRP value. For experimental data tested and assuming uniform activity distribution, the committed effective doses amount between one twenty-fifth to one fiftieth of the values calculated from the ICRP model. The uncertainty of the derived dose coefficients is estimated to be about +/- 50 %.
引用
收藏
页码:205 / 213
页数:9
相关论文
共 50 条
  • [41] Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration
    Tse, FLS
    Laplanche, R
    PHARMACEUTICAL RESEARCH, 1998, 15 (10) : 1614 - 1620
  • [42] Absorption, Metabolism, and Disposition of [14C]SDZ ENA 713, an Acetylcholinesterase Inhibitor, in Minipigs Following Oral, Intravenous, and Dermal Administration
    Francis L. S. Tse
    Robert Laplanche
    Pharmaceutical Research, 1998, 15 : 1614 - 1620
  • [43] Distribution of [14C]suramin in tissues of male rats following a single intravenous dose
    McNally, WP
    DeHart, PD
    Lathia, C
    Whitfield, LR
    LIFE SCIENCES, 2000, 67 (15) : 1847 - 1857
  • [44] Pharmacokinetics, Excretion, and Mass Balance of [14C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men
    Ambery, Claire
    Young, Graeme
    Fuller, Teresa
    Lazaar, Aili L.
    Pereira, Adrian
    Hughes, Adam
    Ramsay, David
    van den Berg, Frans
    Daley-Yates, Peter
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (08): : 901 - 910
  • [45] Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]‑BI 425809 in Healthy Males
    Ute Burkard
    Michael Desch
    Yury Shatillo
    Glen Wunderlich
    Salome Rebecca Mack
    Christina Schlecker
    Aaron M. Teitelbaum
    Pingrong Liu
    Tom S. Chan
    Clinical Drug Investigation, 2022, 42 : 375 - 375
  • [46] Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers
    Bekersky, I
    Fielding, RM
    Dressler, DE
    Kline, S
    Buell, DN
    Walsh, TJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (09): : 963 - 971
  • [47] Metabolism and excretion of BG12 in rats and humans following oral administration of a single oral dose of [14C]BG12
    Xu, Lin
    Dawson, Kate
    Woodworth, James
    Yang, Liyu
    Klunk, Lewis J.
    Stecher, Scott
    Prakash, Chandra
    DRUG METABOLISM REVIEWS, 2009, 41 : 133 - 133
  • [48] Plasma Pharmacokinetics and Routes of Excretion of [14C]-Labeled Arruva, a High-Potency Sweetener, Following Oral Administration to Beagle Dogs
    Casterton, Phillip L.
    Crincoli, Christine M.
    Brathwaite, Witty A.
    Rihner, Marisa O.
    Nikiforov, Andrey I.
    Thomas, Jennifer A.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2014, 33 (03) : 238 - 245
  • [49] Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [14C]aficamten following single oral dose administration to rats
    Grillo, Mark P.
    Sukhun, Rajaa
    Bashir, Mohammad
    Ashcraft, Luke
    Morgan, Bradley P.
    XENOBIOTICA, 2024, 54 (09) : 670 - 685
  • [50] HUMAN MASS BALANCE WITH [14C]-BILASTINE FOLLOWING ORAL ADMINISTRATION TO HEALTHY VOLUNTEERS
    Sologuren, A.
    Lucero, M. L.
    Valiente, R.
    Charles, H.
    Mair, S. J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 106 - 107